社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
爱因斯坦沽
IP属地:广东
+关注
帖子 · 413
帖子 · 413
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
爱因斯坦沽
爱因斯坦沽
·
04-01 15:10
$派格生物医药-B(02565)$
顶住今天的抛压,股价有希望大涨起来
看
70
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
爱因斯坦沽
爱因斯坦沽
·
04-01 15:09
$中国太平(00966)$
消息面上,券商发布报告看好保险股估值修复。报告指出,在“存款搬家”的背景下,居民保险储蓄需求旺盛,预计将推动新业务价值增长;同时,长端利率阶段性企稳,有助于险企资产端业绩向好。此外,各上市险企年报普遍符合或超过市场预期,基本面稳健。报告认为,由负债端开门红销售景气及资产端利率回升带来的保险股估值修复值得期待,并维持行业“增持”评级。这一乐观的行业前景分析,提振了市场对包括中国太平在内的保险板块的信心。
看
70
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
爱因斯坦沽
爱因斯坦沽
·
04-01 15:09
$中慧生物-B(02627)$
中慧在企业创新发展方面取得多项突破性进展。自主研发的一类新药猴痘mRNA疫苗临床试验申请获得中国国家药品监督管理局药品审评中心受理
看
72
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
爱因斯坦沽
爱因斯坦沽
·
04-01 15:08
$百度集团-SW(09888)$
南方财经4月1日电,天眼查知识产权信息显示,近日,北京百度网讯科技有限公司登记“百度健康doctorclaw产品logo”“百度健康Dr.claw产品logo”作品著作权,作品类别均为美术。北京百度网讯科技有限公司成立于2001年6月,法定代表人为梁志祥,注册资本约134.2亿人民币,经营范围包括计算机软硬件及辅助设备零售、计算机软硬件及辅助设备批发、软件开发等,由李彦宏、崔珊珊共同持股。公开资料显示,DoctorClaw是百度健康内测的一款面向医生的专业AI智能助手。
看
517
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
爱因斯坦沽
爱因斯坦沽
·
04-01 15:04
$中国生物制药(01177)$
中国生物制药今日盘中大涨7.98%,引起了市场的广泛关注。 消息面上,该股在盘中出现多笔大手买入交易,其中一笔成交量为84.9万股,成交价为6.35港元,涉资约539万港元;另一笔成交量为85.5万股,成交价为6.34港元,涉资约542万港元。这些大额资金流入直接推动了股价的快速上涨。
看
111
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
爱因斯坦沽
爱因斯坦沽
·
03-31 15:35
$中慧生物-B(02627)$
收盘前股价开始冲起来,今天有机会收阳柱
看
23
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
爱因斯坦沽
爱因斯坦沽
·
03-31 15:34
$比亚迪股份(01211)$
金吾财讯 | 交银国际研报指,比亚迪股份(01211)4Q25实现营收2,377.0亿元,归母净利润92.9亿元,受行业竞争影响毛利率短期承压至17.4%,但严格的费用管控确保了盈利底盘稳固。
看
129
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
爱因斯坦沽
爱因斯坦沽
·
03-31 15:34
$派格生物医药-B(02565)$
派格生物已成功构建覆盖七款针对慢性疾病领域的在研药物管线矩阵。公司核心战略聚焦于代谢性疾病及其并发症的治疗,通过持续创新,内部评估显示多款候选药物兼具“同类首创”(FIC)与“同类最优”(BIC)的双重价值潜力,为未来市场竞争力奠定坚实基础。
看
65
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
爱因斯坦沽
爱因斯坦沽
·
03-31 15:34
$百度集团-SW(09888)$
智东西3月31日消息,今天凌晨,“苹果国行AI突然来了”的消息瞬间刷屏,部分iPhone用户发现自己的系统设置里突然多了“Apple智能与Siri”的选项,并且是可以开启的
看
1,635
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
爱因斯坦沽
爱因斯坦沽
·
03-31 15:33
$中国太平(00966)$
金吾财讯 | 广发证券发布研报指,中国太平(00966)2025年业绩实现翻倍增长,分红超出预期。该行认为业绩高增的核心逻辑在于投资服务业绩明显改善叠加递延所得税转回带来的一次性利好,同时公司分红大幅增加彰显对未来发展的信心。给予该股目标价29.34港元及“买入”评级。
看
52
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
加载更多
暂无粉丝
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"4108557628164870","uuid":"4108557628164870","gmtCreate":1645454559047,"gmtModify":1675866418565,"name":"爱因斯坦沽","pinyin":"aystgaiyinsitangu","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":21,"headSize":3,"tweetSize":413,"questionSize":0,"limitLevel":999,"accountStatus":2,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.02","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"广东","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":548921716465992,"gmtCreate":1775027423448,"gmtModify":1775027425370,"author":{"id":"4108557628164870","authorId":"4108557628164870","name":"爱因斯坦沽","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4108557628164870","idStr":"4108557628164870"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02565\">$派格生物医药-B(02565)$ </a> 顶住今天的抛压,股价有希望大涨起来","listText":"<a href=\"https://laohu8.com/S/02565\">$派格生物医药-B(02565)$ </a> 顶住今天的抛压,股价有希望大涨起来","text":"$派格生物医药-B(02565)$ 顶住今天的抛压,股价有希望大涨起来","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/548921716465992","isVote":1,"tweetType":1,"viewCount":70,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":548926551089552,"gmtCreate":1775027390825,"gmtModify":1775027393261,"author":{"id":"4108557628164870","authorId":"4108557628164870","name":"爱因斯坦沽","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4108557628164870","idStr":"4108557628164870"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/00966\">$中国太平(00966)$ </a> 消息面上,券商发布报告看好保险股估值修复。报告指出,在“存款搬家”的背景下,居民保险储蓄需求旺盛,预计将推动新业务价值增长;同时,长端利率阶段性企稳,有助于险企资产端业绩向好。此外,各上市险企年报普遍符合或超过市场预期,基本面稳健。报告认为,由负债端开门红销售景气及资产端利率回升带来的保险股估值修复值得期待,并维持行业“增持”评级。这一乐观的行业前景分析,提振了市场对包括中国太平在内的保险板块的信心。","listText":"<a href=\"https://laohu8.com/S/00966\">$中国太平(00966)$ </a> 消息面上,券商发布报告看好保险股估值修复。报告指出,在“存款搬家”的背景下,居民保险储蓄需求旺盛,预计将推动新业务价值增长;同时,长端利率阶段性企稳,有助于险企资产端业绩向好。此外,各上市险企年报普遍符合或超过市场预期,基本面稳健。报告认为,由负债端开门红销售景气及资产端利率回升带来的保险股估值修复值得期待,并维持行业“增持”评级。这一乐观的行业前景分析,提振了市场对包括中国太平在内的保险板块的信心。","text":"$中国太平(00966)$ 消息面上,券商发布报告看好保险股估值修复。报告指出,在“存款搬家”的背景下,居民保险储蓄需求旺盛,预计将推动新业务价值增长;同时,长端利率阶段性企稳,有助于险企资产端业绩向好。此外,各上市险企年报普遍符合或超过市场预期,基本面稳健。报告认为,由负债端开门红销售景气及资产端利率回升带来的保险股估值修复值得期待,并维持行业“增持”评级。这一乐观的行业前景分析,提振了市场对包括中国太平在内的保险板块的信心。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/548926551089552","isVote":1,"tweetType":1,"viewCount":70,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":548879906821408,"gmtCreate":1775027369334,"gmtModify":1775027371542,"author":{"id":"4108557628164870","authorId":"4108557628164870","name":"爱因斯坦沽","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4108557628164870","idStr":"4108557628164870"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02627\">$中慧生物-B(02627)$ </a> 中慧在企业创新发展方面取得多项突破性进展。自主研发的一类新药猴痘mRNA疫苗临床试验申请获得中国国家药品监督管理局药品审评中心受理","listText":"<a href=\"https://laohu8.com/S/02627\">$中慧生物-B(02627)$ </a> 中慧在企业创新发展方面取得多项突破性进展。自主研发的一类新药猴痘mRNA疫苗临床试验申请获得中国国家药品监督管理局药品审评中心受理","text":"$中慧生物-B(02627)$ 中慧在企业创新发展方面取得多项突破性进展。自主研发的一类新药猴痘mRNA疫苗临床试验申请获得中国国家药品监督管理局药品审评中心受理","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/548879906821408","isVote":1,"tweetType":1,"viewCount":72,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":548879354704232,"gmtCreate":1775027325665,"gmtModify":1775030763463,"author":{"id":"4108557628164870","authorId":"4108557628164870","name":"爱因斯坦沽","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4108557628164870","idStr":"4108557628164870"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/09888\">$百度集团-SW(09888)$ </a> 南方财经4月1日电,天眼查知识产权信息显示,近日,北京百度网讯科技有限公司登记“百度健康doctorclaw产品logo”“百度健康Dr.claw产品logo”作品著作权,作品类别均为美术。北京百度网讯科技有限公司成立于2001年6月,法定代表人为梁志祥,注册资本约134.2亿人民币,经营范围包括计算机软硬件及辅助设备零售、计算机软硬件及辅助设备批发、软件开发等,由李彦宏、崔珊珊共同持股。公开资料显示,DoctorClaw是百度健康内测的一款面向医生的专业AI智能助手。","listText":"<a href=\"https://laohu8.com/S/09888\">$百度集团-SW(09888)$ </a> 南方财经4月1日电,天眼查知识产权信息显示,近日,北京百度网讯科技有限公司登记“百度健康doctorclaw产品logo”“百度健康Dr.claw产品logo”作品著作权,作品类别均为美术。北京百度网讯科技有限公司成立于2001年6月,法定代表人为梁志祥,注册资本约134.2亿人民币,经营范围包括计算机软硬件及辅助设备零售、计算机软硬件及辅助设备批发、软件开发等,由李彦宏、崔珊珊共同持股。公开资料显示,DoctorClaw是百度健康内测的一款面向医生的专业AI智能助手。","text":"$百度集团-SW(09888)$ 南方财经4月1日电,天眼查知识产权信息显示,近日,北京百度网讯科技有限公司登记“百度健康doctorclaw产品logo”“百度健康Dr.claw产品logo”作品著作权,作品类别均为美术。北京百度网讯科技有限公司成立于2001年6月,法定代表人为梁志祥,注册资本约134.2亿人民币,经营范围包括计算机软硬件及辅助设备零售、计算机软硬件及辅助设备批发、软件开发等,由李彦宏、崔珊珊共同持股。公开资料显示,DoctorClaw是百度健康内测的一款面向医生的专业AI智能助手。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/548879354704232","isVote":1,"tweetType":1,"viewCount":517,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":548878480898008,"gmtCreate":1775027090905,"gmtModify":1775027093452,"author":{"id":"4108557628164870","authorId":"4108557628164870","name":"爱因斯坦沽","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4108557628164870","idStr":"4108557628164870"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/01177\">$中国生物制药(01177)$ </a> 中国生物制药今日盘中大涨7.98%,引起了市场的广泛关注。 消息面上,该股在盘中出现多笔大手买入交易,其中一笔成交量为84.9万股,成交价为6.35港元,涉资约539万港元;另一笔成交量为85.5万股,成交价为6.34港元,涉资约542万港元。这些大额资金流入直接推动了股价的快速上涨。","listText":"<a href=\"https://laohu8.com/S/01177\">$中国生物制药(01177)$ </a> 中国生物制药今日盘中大涨7.98%,引起了市场的广泛关注。 消息面上,该股在盘中出现多笔大手买入交易,其中一笔成交量为84.9万股,成交价为6.35港元,涉资约539万港元;另一笔成交量为85.5万股,成交价为6.34港元,涉资约542万港元。这些大额资金流入直接推动了股价的快速上涨。","text":"$中国生物制药(01177)$ 中国生物制药今日盘中大涨7.98%,引起了市场的广泛关注。 消息面上,该股在盘中出现多笔大手买入交易,其中一笔成交量为84.9万股,成交价为6.35港元,涉资约539万港元;另一笔成交量为85.5万股,成交价为6.34港元,涉资约542万港元。这些大额资金流入直接推动了股价的快速上涨。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/548878480898008","isVote":1,"tweetType":1,"viewCount":111,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":548532449612088,"gmtCreate":1774942535882,"gmtModify":1774942538077,"author":{"id":"4108557628164870","authorId":"4108557628164870","name":"爱因斯坦沽","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4108557628164870","idStr":"4108557628164870"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02627\">$中慧生物-B(02627)$ </a> 收盘前股价开始冲起来,今天有机会收阳柱","listText":"<a href=\"https://laohu8.com/S/02627\">$中慧生物-B(02627)$ </a> 收盘前股价开始冲起来,今天有机会收阳柱","text":"$中慧生物-B(02627)$ 收盘前股价开始冲起来,今天有机会收阳柱","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/548532449612088","isVote":1,"tweetType":1,"viewCount":23,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":548531894698424,"gmtCreate":1774942497246,"gmtModify":1774942499626,"author":{"id":"4108557628164870","authorId":"4108557628164870","name":"爱因斯坦沽","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4108557628164870","idStr":"4108557628164870"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/01211\">$比亚迪股份(01211)$ </a> 金吾财讯 | 交银国际研报指,比亚迪股份(01211)4Q25实现营收2,377.0亿元,归母净利润92.9亿元,受行业竞争影响毛利率短期承压至17.4%,但严格的费用管控确保了盈利底盘稳固。","listText":"<a href=\"https://laohu8.com/S/01211\">$比亚迪股份(01211)$ </a> 金吾财讯 | 交银国际研报指,比亚迪股份(01211)4Q25实现营收2,377.0亿元,归母净利润92.9亿元,受行业竞争影响毛利率短期承压至17.4%,但严格的费用管控确保了盈利底盘稳固。","text":"$比亚迪股份(01211)$ 金吾财讯 | 交银国际研报指,比亚迪股份(01211)4Q25实现营收2,377.0亿元,归母净利润92.9亿元,受行业竞争影响毛利率短期承压至17.4%,但严格的费用管控确保了盈利底盘稳固。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/548531894698424","isVote":1,"tweetType":1,"viewCount":129,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":548531867344960,"gmtCreate":1774942477156,"gmtModify":1774942479296,"author":{"id":"4108557628164870","authorId":"4108557628164870","name":"爱因斯坦沽","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4108557628164870","idStr":"4108557628164870"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02565\">$派格生物医药-B(02565)$ </a> 派格生物已成功构建覆盖七款针对慢性疾病领域的在研药物管线矩阵。公司核心战略聚焦于代谢性疾病及其并发症的治疗,通过持续创新,内部评估显示多款候选药物兼具“同类首创”(FIC)与“同类最优”(BIC)的双重价值潜力,为未来市场竞争力奠定坚实基础。","listText":"<a href=\"https://laohu8.com/S/02565\">$派格生物医药-B(02565)$ </a> 派格生物已成功构建覆盖七款针对慢性疾病领域的在研药物管线矩阵。公司核心战略聚焦于代谢性疾病及其并发症的治疗,通过持续创新,内部评估显示多款候选药物兼具“同类首创”(FIC)与“同类最优”(BIC)的双重价值潜力,为未来市场竞争力奠定坚实基础。","text":"$派格生物医药-B(02565)$ 派格生物已成功构建覆盖七款针对慢性疾病领域的在研药物管线矩阵。公司核心战略聚焦于代谢性疾病及其并发症的治疗,通过持续创新,内部评估显示多款候选药物兼具“同类首创”(FIC)与“同类最优”(BIC)的双重价值潜力,为未来市场竞争力奠定坚实基础。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/548531867344960","isVote":1,"tweetType":1,"viewCount":65,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":548532104753200,"gmtCreate":1774942448964,"gmtModify":1774942451315,"author":{"id":"4108557628164870","authorId":"4108557628164870","name":"爱因斯坦沽","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4108557628164870","idStr":"4108557628164870"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/09888\">$百度集团-SW(09888)$ </a> 智东西3月31日消息,今天凌晨,“苹果国行AI突然来了”的消息瞬间刷屏,部分iPhone用户发现自己的系统设置里突然多了“Apple智能与Siri”的选项,并且是可以开启的","listText":"<a href=\"https://laohu8.com/S/09888\">$百度集团-SW(09888)$ </a> 智东西3月31日消息,今天凌晨,“苹果国行AI突然来了”的消息瞬间刷屏,部分iPhone用户发现自己的系统设置里突然多了“Apple智能与Siri”的选项,并且是可以开启的","text":"$百度集团-SW(09888)$ 智东西3月31日消息,今天凌晨,“苹果国行AI突然来了”的消息瞬间刷屏,部分iPhone用户发现自己的系统设置里突然多了“Apple智能与Siri”的选项,并且是可以开启的","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/548532104753200","isVote":1,"tweetType":1,"viewCount":1635,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":548531720931328,"gmtCreate":1774942433202,"gmtModify":1774942435535,"author":{"id":"4108557628164870","authorId":"4108557628164870","name":"爱因斯坦沽","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4108557628164870","idStr":"4108557628164870"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/00966\">$中国太平(00966)$ </a> 金吾财讯 | 广发证券发布研报指,中国太平(00966)2025年业绩实现翻倍增长,分红超出预期。该行认为业绩高增的核心逻辑在于投资服务业绩明显改善叠加递延所得税转回带来的一次性利好,同时公司分红大幅增加彰显对未来发展的信心。给予该股目标价29.34港元及“买入”评级。","listText":"<a href=\"https://laohu8.com/S/00966\">$中国太平(00966)$ </a> 金吾财讯 | 广发证券发布研报指,中国太平(00966)2025年业绩实现翻倍增长,分红超出预期。该行认为业绩高增的核心逻辑在于投资服务业绩明显改善叠加递延所得税转回带来的一次性利好,同时公司分红大幅增加彰显对未来发展的信心。给予该股目标价29.34港元及“买入”评级。","text":"$中国太平(00966)$ 金吾财讯 | 广发证券发布研报指,中国太平(00966)2025年业绩实现翻倍增长,分红超出预期。该行认为业绩高增的核心逻辑在于投资服务业绩明显改善叠加递延所得税转回带来的一次性利好,同时公司分红大幅增加彰显对未来发展的信心。给予该股目标价29.34港元及“买入”评级。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/548531720931328","isVote":1,"tweetType":1,"viewCount":52,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"followers","isTTM":false}